A recent Phase I/II study of DSF and Cu++ with concurrent radiation therapy and TMZ for newly diagnosed glioblastoma demonstrated promising preliminary efficacy for a subset of tumors with IDH1, BRAF, and NF1 mutations [32]. The gene discussed is IDH1; the disease is glioblastoma.